

## Institutional Biosafety Committee - Regular Meeting

Thursday, September 3, 2026

Zoom

### Meeting Minutes

|                                    |                                                                                                                                                       |
|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| VOTING MEMBERS PRESENT:            | G. Babcock, K. Burns, J. Corcoran, G. Dean, D. Elsaesser, M. Espinola, S. Kasper, R. Larson, E. Otten, T. Rausch, F. Schaefer, E. Serafin, G. Smulian |
| VOTING MEMBERS NOT PRESENT:        | S. Apewokin                                                                                                                                           |
| AD HOC MEMBERS/CONSULTANTS/GUESTS: | P. DeBrosse, L. Elkin, T. Gulley, T. Lindley, A. Perry, O'Rourke, J. Strasser                                                                         |
| IBC STAFF:                         | D. Healy, B. Kesavalu                                                                                                                                 |

K. Burns convened the meeting at 12:00 p.m.

- I. **Conflicts of Interest** - No conflicts were identified.
- II. **Minutes** - Minutes from the previous IBC meeting (08/06/26) was approved (11: YES/0: NO/1: Abstained)
- III. **Old Business** - R. Kovall – Corrective and Preventative Action Plan
  - While awaiting R. Kovall's arrival at the scheduled meeting time (12:15 p.m.), the IBC discussed some potential corrective measures:
    - a) The PI is expected to acknowledge and respond promptly to all future communications from the IBC and BSO. All communications regarding safety must occur directly with the PI and not through a lab representative.
    - b) Implementation of a PI-led laboratory self-inspection checklist addressing lab safety and appropriate attire.
    - c) Require completion of the Biosafety 101 training
    - d) Periodic/random spot inspections to verify continued compliance.
  - The committee discussed the need for the development of an SOP outlining the process for addressing repeated or unresolved non-compliance.
  - PI and his laboratory staff failed to attend the requested meeting.
  - **Motion:** The IBC Chair will send a formal letter to the Department Chair and the Dean of Research, with copies to the PI and Compliance Officer including:
    - The history of non-compliance and lack of PI's response.
    - PI will be given seven business days to either submit a corrective action plan or schedule a meeting with the IBC/Biosafety Office to address the concerns.
    - If the PI does not respond within the specified timeframe, the IBC protocol will be suspended.

Motion was approved (13: YES/0: NO/0: Abstained)

#### IV. New Business

- A. **Primary Protocols** (No protocol)
- B. **Secondary Protocols** (3 protocols)

| IBC Protocol Number      | PI                                                                                                     | Type of Submission | IBC Items                       |              |
|--------------------------|--------------------------------------------------------------------------------------------------------|--------------------|---------------------------------|--------------|
| 1. 26-08-24-01           | Faber                                                                                                  | Renewal Clinical   | CAR -T cells (P-BCMA-ALLO1-001) |              |
| IBC Requests:            | 1. <b>Section III. B</b> - Last certification date cannot be in the future. Revise section accordingly |                    |                                 |              |
| Motion                   | Approve upon modifications addressing outlined issues.                                                 |                    |                                 |              |
| Voting Result & Dual Use | YES: 13                                                                                                | NO: 0              | Abstained: 0                    | Dual Use? No |

| IBC Protocol Number      | PI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Type of Submission | Biosafety Level | IBC Items                                                                                    |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------|----------------------------------------------------------------------------------------------|
| 2. 26-08-17-01           | Barrile                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Renewal            | BSL2            | <i>in vitro</i> : HDM (established and primary cells, including iPSCs, organoids, and blood) |
| IBC Requests:            | 1. Lab staff must complete their BBP training;<br><u>Main Form – General Safety:</u><br>2. <b>Section I. A</b> and <b>I. B</b> - Include UC mail code and Office phone; If not applicable, say N/A;<br>3. <b>Section II. B</b> - The information about experiments is already provided in your Form C. For this section, just maintain the focus of your research, explain your microfluidic <i>in vitro</i> model and provide its relevance;<br>4. <b>Section III. A</b> - Are other equipment like a vortex or sonicator used to process human derived materials? If so, include aerosol mitigation plans;<br>5. <b>Section III. B - Additional Information</b> - Remove the sentence about training courses since it is not applicable to this section;<br><u>Form C – Human and NHP Derived Materials:</u><br>6. <b>Section I - Established Cells</b> - Provide the source of the U87 Brain tumor Cell Line;<br>7. <b>Section II. A</b> – In a previous section, you mentioned "bioprinting". If it includes the use of human cells include details and explain it in this section. |                    |                 |                                                                                              |
| Motion                   | Approve upon modifications addressing outlined issues.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |                    |                 |                                                                                              |
| Voting Result & Dual Use | YES: 12<br>(one member did not vote)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | NO: 0              | Abstained: 0    | Dual Use? No                                                                                 |

| IBC Protocol Number      | PI                                                                                                                                                                                                                                                             | Type of Submission | Biosafety Level | IBC Items                                                                       |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------------|---------------------------------------------------------------------------------|
| 3.26-08-12-01            | Rollmann                                                                                                                                                                                                                                                       | Renewal            | BSL1            | <i>in vitro</i> : <i>Escherichia coli</i> (RG1), genetically modified fruit fly |
| IBC Requests:            | <u>Main Form – General Safety:</u><br>1. <b>Section I. B</b> - Enter lab phone number or enter N/A if there is no office number;<br>2. <b>Section III. A</b> - For all the equipment listed above, consult the eManual and list aerosol mitigation strategies. |                    |                 |                                                                                 |
| Motion                   | Approve upon modifications addressing outlined issues.                                                                                                                                                                                                         |                    |                 |                                                                                 |
| Voting Result & Dual Use | YES: 13                                                                                                                                                                                                                                                        | NO: 0              | Abstained: 0    | Dual Use? No                                                                    |

**V. Protocol Updates** - July 30<sup>th</sup> to August 27<sup>th</sup> (18 protocols)

1. IBC# 25-03-19-02 - PI: Plas - Personnel
2. IBC# 25-04-15-01 - PI: Wise-Draper - Personnel
3. IBC# 25-07-18-01 - PI: Hou - Personnel, Location
4. IBC# 25-07-08-01 - PI: Brewer - Personnel
5. IBC# 25-08-11-02 - PI: Fan G - Personnel
6. IBC# 24-01-18-01 - PI: Ikegami - Personnel
7. IBC# 26-05-14-01 - PI: Zhang X - Add human mammary tumor tissue
8. IBC# 26-03-09-01 - PI: Wilson G - Personnel
9. IBC# 25-02-14-01 - PI: Drosatos - Personnel
10. IBC# 24-10-10-01 - PI: Gao - Personnel
11. IBC# 26-02-25-01 - PI: Shi - BSL2 Amendment - Add retroviral vector and genes (LAMP1 and DNase II)
12. IBC# 24-09-04-01 - PI: Diao - Location
13. IBC# 23-05-17-01 - PI: Davidson S - Location
14. IBC# 26-03-02-01 - PI: Chella Krishnan - Personnel
15. IBC# 26-02-20-02 - PI: Martin - Location
16. IBC# 25-03-19-01 - PI: Owens - Personnel
17. IBC# 24-12-09-01 - PI: Deepe - Personnel
18. IBC# 25-07-03-01 - PI: Natarajan - Personnel

**VI. Reports**

- A. IBC/BSOf - New NIH Biosafety Policy - Highlights
  - M. Espinola presented the highlights of the new NIH Policy and encouraged all to provide feedback by 10/19/26.

**VII. Educational Materials/Updates**

- A. [Request for Comment: Draft NIH Biosafety Policy for Research](#) August 2026
- B. [Notes from the Field: Misidentification of a Specimen as \*Neisseria meningitidis\* During a University Classroom Laboratory Exercise — Utah, 2025](#) July 2026
- C. [AI-designed viral genomes](#) August 2026
- D. [New rules on risky biology studies get mixed reviews](#) August 2026

K. Burns adjourned the meeting at 12:57 p.m.

